Study: Heartburn Drugs OK With Plavix?
No Increase in Heart Attack Risk Reported; Findings Differ From Other Studies
Aug. 31, 2009 -- Heart patients who take the anti-clotting drug Plavix may safely take an acid-reducing proton pump inhibitor (PPI) drug, an analysis of two previously reported studies suggests.
The new findings seem to contradict several recent studies showing negative outcomes in heart patients who took Plavix with a PPI, especially the drug Prilosec.
In the most recent study, reported in March, heart attack patients who took Plavix with a PPI were more likely to have a second heart attack than patients who took Plavix without a PPI.
Plavix and another anti-clotting drug, Effient, which was approved by the FDA in June, are prescribed to heart attack patients along with aspirin to prevent blood clots that can cause a second heart attack or stroke.
PPIs, such as Prilosec, Nexium, Prevacid, and Protonix, are often given to reduce the risk of stomach or intestinal bleeding from anti-clotting drugs.
PPIs OK With Plavix
The new analysis showed no increase in heart attack, stroke, or cardiovascular death risk in patients taking PPIs while also taking Plavix or Effient.
“We did not find use of a PPI to be associated with a higher risk of cardiovascular events for patients taking either of these drugs,” lead researcher Michelle L. O’Donoghue, MD, of Boston’s Brigham and Women’s Hospital, tells WebMD. “This raises the question as to why the current findings differ from those of prior analyses.”
One theory is that PPIs may be prescribed most often to the sickest heart attack patients, he says.
The studies included in the analysis were sponsored by Effient manufacturer Eli Lilly & Co. and were designed to compare the drug to Plavix.
The larger of the two trials included about 13,600 patients who had a previous heart attack or unstable angina treated with one of the two drugs.
Patients in the trial were younger and less likely to have diabetes or kidney failure than patients who participated in many of the earlier trials showing worse outcomes with PPI use.
“This may help explain why patients on a PPI seem to do more poorly than other patients in many studies,” O’Donoghue says.
One-third of the patients in the trial were also taking a PPI, but PPI use was not found to be associated with an increased risk of a second heart attack, stroke, or cardiovascular death with either of the two anti-clotting drugs.